LONDON (Alliance News) - Scancell Holdings PLC on Wednesday said it will secure a European patent for its Moditope immunotherapy platform in mid-June.
The cancer treatment developer said the patent will provide broad protection for its Moditope vaccines, including any citrullinated epitopes for the treatment of cancer.
Counterparts to this patent have been filed in Australia, South Africa, US and certain countries in Asia and South America.
"This is a key patent for Scancell," said Chief Scientific Officer Lindy Durrant. "We are now well positioned to develop a pipeline of new Moditope therapies with the potential to address the unmet need across a broad range of hard to treat cancers."
Shares in Scancell were trading 3.5% lower at 14.00 pence each on Wednesday.
Scancell Holdings (SCLP)